Emergent Biosolutions (EBS) Earnings Date & Reports

Key Takeaways

• Third quarter 2026 revenue came in at roughly $110 million, within management's $110–$130 million guidance range but below the analyst consensus of about $123 million.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) turned negative at approximately $5 million, with an adjusted gross margin of 28%.
• Management lowered full-year 2026 guidance to $600–$645 million in revenue and $110–$140 million in adjusted EBITDA, reflecting softer naloxone pricing and MCM (medical countermeasures) delivery timing.
• The company continued to strengthen its balance sheet, cutting gross debt to $514 million and holding net leverage steady at 2.4 times trailing adjusted EBITDA.
• An August restructuring program is expected to deliver roughly $40 million in annualized savings, with most of the benefit materializing in 2027.
• Shares moved lower following the release, as results came in below Wall Street's top-line expectations.
• For more context, explore Emergent BioSolutions' Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• Investors seeking additional data-driven signals can also explore Trending AI Robots for automated market analysis.

Earnings Context and Why It Matters

Emergent BioSolutions, best known for its NARCAN nasal spray and government medical countermeasures, reported third quarter 2026 results on November 2, 2026. The quarter reflects an anticipated step-down after accelerated U.S. government deliveries in the first half of the year, combined with ongoing competitive pressure in the naloxone market. Investors are watching closely because the company is in the middle of a multi-year turnaround aimed at reducing debt and stabilizing margins. The results matter for gauging whether Emergent can protect its naloxone franchise against generics while sustaining steady MCM (medical countermeasures) contract wins from U.S. and international government customers.

Reported Results

Emergent reported third quarter 2026 revenue of approximately $110 million, within its prior guidance range of $110–$130 million but below the roughly $123 million consensus estimate and down sharply from $231 million in the year-ago period. The decline primarily reflected the timing of MCM product deliveries, which were pulled forward into the second quarter, along with softer naloxone performance.

Adjusted EBITDA was negative $5 million for the quarter, and adjusted gross margin was 28%, pressured by product mix and competitive dynamics in the naloxone market. Year-to-date revenue reached $500 million, with adjusted EBITDA of $128 million (a 25% margin) and operating cash flow of $122 million.

Management trimmed full-year 2026 guidance, now projecting revenue of $600–$645 million (down from $645–$675 million) and adjusted EBITDA of $110–$140 million (down from $130–$150 million). On the balance sheet, cash stood at $176 million with total liquidity of $226 million, gross debt was $514 million versus $693 million a year earlier, and net leverage remained stable at 2.4 times trailing adjusted EBITDA.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Emergent BioSolutions, it offers a streamlined way to surface signals and compare opportunities across the healthcare and biotech landscape.

Market Reaction and Investor Sentiment

Emergent BioSolutions shares moved lower following the release, as the quarter's revenue came in below analyst expectations and the company reduced its full-year outlook. Investor sentiment has been cautious around the naloxone franchise, where new over-the-counter (OTC) and generic competitors have driven pricing and volume pressure in U.S. channels. The reduced guidance reinforced concerns that near-term profitability will remain constrained, even as management highlights disciplined cost control and progress on debt reduction. The positive elements of the report — strong cash flow conversion, lower gross debt, and restructuring savings — were partly overshadowed by the softer top line and the downward revision to full-year profitability.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors should focus on several themes that will shape Emergent's trajectory. The first is the pace of MCM (medical countermeasures) contract activity. The company executed a $24 million CYFENDUS contract modification in the quarter and supplied products to 13 countries, but government procurement is inherently lumpy, and the timing of awards can swing quarterly results significantly.

Second, the naloxone franchise remains a central risk. Management expects the U.S. market to stay competitive on pricing and volume, while Canadian branded NARCAN sales provide some offset. Whether pricing stabilizes or erodes further will directly influence gross margins.

Finally, the company's restructuring and balance-sheet progress bear watching. The August cost-reduction program is projected to generate about $40 million in annualized savings, with the full run-rate expected in 2027. Meanwhile, a $75 million bond repurchase completed for $68 million in cash has already lowered interest expense and gross debt. Continued cash generation, further debt reduction, and the pace of restructuring benefits will be key indicators of whether Emergent can rebuild profitability through 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations